Hercules, CA October 22, 2013 More accurate and precise assessment of copy number variation (CNV), the number of copies of a particular gene that are present in a genome, may lead to improved diagnosis and therapy for cancer and other diseases including autoimmune disorders. However, current technologies to determine copy number can be inaccurate, labor intensive, or prohibitively costly, diminishing their effectiveness in clinical applications.
Using Bio-Rad Laboratories' Droplet Digital PCR (ddPCR) technology, researchers can rapidly, accurately, and economically determine copy number states. Groups from the University of California, Davis, and the University of Colorado School of Medicine, among others, will present promising new research results at this year's annual meeting of the American Society of Human Genetics (ASHG), held in Boston from October 22-25, 2013.
"Since its introduction in 2011, Bio-Rad Laboratory's ddPCR technology has demonstrated the potential to be a transformative technology based on its greater precision, reproducibility, and sensitivity than conventional approaches such as real-time PCR," said George Karlin-Neumann, the scientific affairs director at Bio-Rad's Digital Biology Center.
Less than two years since Bio-Rad brought digital PCR systems to the market, studies using ddPCR assays have resulted in nearly 50 peer-reviewed publications.
Using ddPCR to Improve Pediatric Care
One example of how CNV determination with ddPCR technology shows promise for clinical
|Contact: Ken Li|